Drug Database
ES

escitalopram + clonazepam (Citapure Plus)

✓ Approved

A. N. Pharmacia Laboratories · GABRA1 · Small Molecule

What is escitalopram + clonazepam?

escitalopram + clonazepam is a small molecule developed by A. N. Pharmacia Laboratories. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesCitapure Plus
CompanyA. N. Pharmacia Laboratories
Drug ClassSmall Molecule
Molecular TargetGABRA1, GABRA2, GABRA3, GABRA4, SLC6A4
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, A. N. Pharmacia Laboratories

Mechanism of Action

Molecular Targets

escitalopram + clonazepam acts on 5 molecular targets:

GABRA1gamma-aminobutyric acid type A receptor alpha1 subunit (ECA4, EJM)
GABRA2gamma-aminobutyric acid type A receptor alpha2 subunit (EIEE78, DEE78)
GABRA3gamma-aminobutyric acid type A receptor alpha3 subunit (EPILX2)
GABRA4gamma-aminobutyric acid type A receptor alpha4 subunit ()
SLC6A4solute carrier family 6 member 4 (SERT1, 5-HTTLPR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

escitalopram + clonazepam is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersBipolar I disorder✓ Approved
Psychiatric disordersGeneralised anxiety disorder✓ Approved

Related Research Articles

PubMedClinical pharmacology and therapeutics2026-10-15

Reprocessing Mass Spectra from Therapeutic Drug Monitoring to Unveil Proton Pump Inhibitor Use and Quantify Phenoconversion of Escitalopram Metabolism in CYP2C19-Genotyped Patients.

Hole Kristine K, Wollmann Birgit M BM, Stingl Julia Carolin JC, Molden Espen E

Escitalopram is a frequently prescribed antidepressant drug. CYP2C19 genotype is a major determinant of escitalopram metabolism and treatment outcome. However, real-life studies show a high degree of genotype-phenotype mismatch in escitalopram metabolism. The present study aimed to identify comedication with proton pump inhibitors (PPIs) and quantify phenoconversion of escitalopram metabolism in CYP2C19-genotyped patients by reprocessing high-resolution mass spectra from therapeutic drug monitoring (TDM) analyses. Patients were included from a combined TDM/pharmacogenetics (PGx) laboratory facility in Oslo, Norway. TDM profiles of escitalopram and CYP2C19 genotypes were available in the laboratory database. Reprocessing of high-resolution mass spectra by exact mass and fragment detection identified possible comedication with pantoprazole, esomeprazole/omeprazole or lansoprazole using mzCloud reference library. Patients were grouped as normal metabolizers (NMs), intermediate metabolizers (IMs), poor metabolizers (PMs), rapid metabolizers (RM), or ultrarapid metabolizers (UM). Primary outcome measure was N-desmethylescitalopram-to-escitalopram metabolic ratio (MR; CYP2C19 biomarker) in UMs vs. PMs. 2818 patients were included, constituting 2373 without and 445 (15.8%) with PPIs. Most patients were females (64.2%). Regarding CYP2C19 phenotype distribution, the cohort comprised 39.3% NMs, 29.3% IMs, 2.6% PMs, 24.6% RMs, and 4.2% UMs. Escitalopram MR was 4.5-fold higher in CYP2C19 UMs vs. PMs without PPIs (P < 0.001), while this difference was 2.8-fold in pantoprazole users (P < 0.001), and 1.8-fold in esomeprazole/omeprazole users (P = 0.2). In conclusion, PPIs show significant phenoconversion of CYP2C19-mediated escitalopram metabolism with esomeprazole/omeprazole exhibiting a stronger effect than pantoprazole. The novel method for identification of interacting comedications in TDM samples illustrates the innovative potential of high-resolution mass spectrometry in precision medicine.

PMID 42876187
Read full article →
PubMedJournal of Ayurveda and integrative medicine2026-10-11

Exploring the potential benefits of Shirodhara as an add-on therapy for alleviating post-COVID anxiety and depression: A case study.

Shamkuwar Manoj M, Pv Anandaraman A, Kataria Dinesh D, Bhatted Santosh S et al.

In this case study, we present a 31-year-old female, a homemaker, who developed persistent symptoms of anxiousness, fatigue, weakness, irritation, anger issues, and difficulty concentrating for nearly 12 months following recovery from COVID-19. She was diagnosed by a consulting psychiatrist with post-COVID anxiety with depression, and had been on anxiolytic and antidepressant medications for the past ten months. She underwent Shirodhara (dripping of medicated oil on the forehead) using Balashwagandhadi taila for 14 days as an add-on therapy, while continuing her conventional medications. Assessments at baseline, 8th day, 15th day, and 30th day showed progressive improvements: Hamilton Anxiety Rating Scale (HAM-A) scores reduced from 42 to 10, Hamilton Depression Rating Scale (HDRS) from 23 to 6, Patient Health Questionnaire-9 (PHQ-9) from 24 to 1, and Flanagan Quality of Life Scale (QOLS) improved from 59 to 79 by the 30th day. Serum cortisol was 3.09 μg/dL at baseline, below the normal range, and returned to the normal physiological range (11.76 μg/dL) on the 15th day, reflecting improved stress adaptation. C-Reactive Protein remained stable, while Systemic Immune-Inflammation Index showed a transient, non-pathological rise within normal limits. Also, based on the evaluation and recommendation of the psychiatrist, the dosage of conventional medications was reduced: Propranolol was tapered from 20 mg twice daily to once daily, Clonazepam 0.5 mg at bedtime was shifted to as-needed use, and Omeprazole was discontinued. This case highlights the potential role of Shirodhara as an adjunctive therapy in post-COVID anxiety, along with depression. These findings require validation through larger studies with long-term follow-up.

PMID 42858603
Read full article →
PubMedbioRxiv : the preprint server for biology2026-10-08

Effects of dopamine and serotonin on persistence for delayed rewards in humans.

Lempert Karolina M KM, Zaneski Laura L, Ramakrishnan Arjun A, Wolf Daniel H DH et al.

People often must decide how long to continue waiting for rewards that will arrive at an uncertain time in the future. We propose that these persistence decisions involve weighing the benefits of continued waiting against opportunity costs of waiting, a balance that may shift over time. This framework suggests that persistence decisions share neural mechanisms with foraging decisions, which require ongoing comparisons between a current resource and possible alternatives. Dopamine and serotonin have been proposed to play opposing roles in foraging, with dopamine promoting exploration and serotonin promoting exploitation. Here we investigated their roles in persistence. In a within-subjects, double-blind, placebo-controlled study in young adults ( n = 42), we examined the effects of increasing dopamine with L-dopa and increasing serotonin with escitalopram. We predicted that L-dopa would decrease persistence and escitalopram would increase it. Participants also completed patch-foraging, time perception, risk tolerance, and temporal discounting tasks to explore potential mechanisms of drug effects on persistence. Escitalopram increased persistence, after adjusting for the effects of anxiety and condition order, such that participants waited longer for rewards after taking the serotonergic drug. L-dopa did not influence persistence. In exploratory analyses controlling for age, however, L-dopa reduced persistence and increased exploration in foraging.

PMID 42845435
Read full article →
PubMedRivista di psichiatria2026-10-08

[Differential diagnosis between Bipolar Disorder and behavioral variant Frontotemporal Dementia: the role of longitudinal neuropsychological assessment. A Case Report.]

Rendace Lidia L, Foti Andrea A, Altavista Maria Concetta MC

Bipolar Disorder (BD) and the behavioral variant of Frontotemporal Dementia (bvFTD) can present overlapping clinical features in their early stages, characterized by disinhibition, euphoria, and executive function deficits. Differential diagnosis is particularly challenging when behavioral symptoms are accompanied by evidence of cortical atrophy on neuroimaging. We describe the case of a 48-year-old woman diagnosed with Type I BD since age 25, referred for suspected bvFTD due to a progressive decline in memory functions and sleep disturbances. At the time of evaluation (T0), the patient had been on long-term treatment with aripiprazole, paroxetine, chlorpromazine, and clonazepam. A brain MRI was performed, and a second-level neuropsychological battery was administered to assess memory, attention, executive functions, language, and praxic functions. The entire protocol was repeated after two years (T1). At T0, analysis revealed marked deficits in executive functions, complex attention, and episodic memory; MRI showed moderate bilateral frontoparietal cortical atrophy. At follow-up (T1), despite the structural finding of atrophy, a complete normalization of the cognitive profile was observed, with performance returning to within normal limits for age and education. The longitudinal improvement confirms that the deficits detected at T0 were an expression of the clinical state of BD rather than a progressive neurodegenerative process. This case emphasizes the fundamental importance of longitudinal neuropsychological assessment and a multidisciplinary approach to avoid misdiagnosis and to optimize the pharmacological treatment of affective and psychotic symptoms.

PMID 42847037
Read full article →
PubMedNeurobiology of pain (Cambridge, Mass.)2026-10-06

Cooling a burning mouth: is TRPM8 the therapeutically relevant target of clonazepam in burning mouth disorder?

Elkin Logan L, Marchant Jonathan S JS

Burning mouth disorder (BMD) is an extremely painful oral condition that occurs at the highest prevalence in post-menopausal women. Treatment options remain limited and remission rates poor, highlighting a need for identification of relevant molecular targets that can be prosecuted for effective therapeutics. One treatment that realizes benefit in patients with burning mouth disorder is clonazepam, a benzodiazepine known to work by augmenting currents through gamma aminobutyric acid A (GABAA) ion channels to inhibit neuronal firing. Here, we highlight an ancillary target for clonazepam as the transient receptor potential melastatin 8 (TRPM8) ion channel. In this commentary, evidence supporting the idea that TRPM8 acts as the therapeutically relevant local mediator of clonazepam action in BMD is summarized, with the goal of spurring new treatments for this debilitating and painful condition.

PMID 42835698
Read full article →
PubMedEpilepsy & behavior reports2026-10-06

Status epilepticus as a novel etiology of Lance-Adams syndrome: a case report.

Wang Fuli F, Xu Lei L, Huang Ting T, Liu Xing X et al.

Lance-Adams syndrome (LAS) is a rare neurological disorder characterized by action myoclonus. The majority of reported cases have occurred following resuscitation from cardiopulmonary arrest, and to our knowledge, no previous case has been documented in the setting of status epilepticus. In this article, we report a patient who developed LAS secondary to status epilepticus. This single-case report suggests that combination therapy with levetiracetam and clonazepam may be effective. The clinical manifestations of LAS secondary to status epilepticus were milder than those typically observed with other etiologies, and the patient achieved a favorable clinical outcome. However, these preliminary findings are based on isolated evidence and warrant confirmation in larger studies.

PMID 42835558
Read full article →

+8324 more articles available with a free account

Sign up free to view all articles →

Ask about escitalopram + clonazepam